Figure 3From: A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG) Progression-free survival by KLF12 + TFF2 gene expression. a) Control set. b) Bevacizumab qPCR set.Back to article page